The core consists of two components located at the Baylor Institute for Immunology Research (BUR) and the? Rockefeller University (RU). The primary objective of Cell Core will be to prepare DC vaccines from patients? with stage IV melanoma (Projects by Banchereau, Palucka, and Fay, BIIR) for the clinical trials proposed? in this Program Project. Three types of DC vaccine will be generated: i) DCs derived from CD34+? hematopoietic progenitors [CD34-DC] (Projects by Banchereau and Palucka)and ii) monocyte-derived DCs fMDCs] generated in cultures with GM-CSF and TNF (Projects by Banchereau and Fay). Tumor antigens will be loaded on vaccines in the form of i) peptides, ii) killed allogeneic melanoma cells, and iii) autologous myeloma cells. The estimated number of vaccines, based on the assumption that 75% of enrolled patients will qualify for full vaccination schedule, that will be prepared by the Core over the 5 years approaches approximately 1200 vaccines at BUR and approximately 400 vaccines at RU. Both Cores are operational and have already released substantial numbers of vaccines for clinical studies in healthy volunteers, patients with metastatic melanoma or with myeloma. The Core at BUR has thus far released >400 vaccines and the process has been successfully audited by the FDA. The Core will follow standard operating procedures that have been established at each institution for the generation of each type of DC. QA program is in place at both Institutions. Secondary objectives of Cell Core include: 1) development and? implementation of assays for potency assessment of DC vaccines, 2) development of closed system for DC? vaccine generation, and 3) development of cryopreserved vaccine and validation of its stability.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA084512-05A2
Application #
7122677
Study Section
Subcommittee G - Education (NCI)
Project Start
2006-03-01
Project End
2009-05-31
Budget Start
2006-03-01
Budget End
2007-05-31
Support Year
5
Fiscal Year
2006
Total Cost
$151,395
Indirect Cost
Name
Baylor Research Institute
Department
Type
DUNS #
145745022
City
Dallas
State
TX
Country
United States
Zip Code
75204
Speake, Cate; Presnell, Scott; Domico, Kelly et al. (2015) An interactive web application for the dissemination of human systems immunology data. J Transl Med 13:196
Rongvaux, Anthony; Willinger, Tim; Martinek, Jan et al. (2014) Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32:364-72
Palucka, Karolina; Banchereau, Jacques (2013) Human dendritic cell subsets in vaccination. Curr Opin Immunol 25:396-402
Palucka, Karolina; Banchereau, Jacques (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39:38-48
Obermoser, Gerlinde; Presnell, Scott; Domico, Kelly et al. (2013) Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 38:831-44
Banchereau, Jacques; Thompson-Snipes, LuAnn; Zurawski, Sandra et al. (2012) The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming. Blood 119:5742-9
Banchereau, Jacques; Zurawski, Sandra; Thompson-Snipes, LuAnn et al. (2012) Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming. Proc Natl Acad Sci U S A 109:18885-90
Palucka, Karolina; Banchereau, Jacques (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-77
Palucka, Karolina; Ueno, Hideki; Roberts, Lee et al. (2011) Dendritic cell subsets as vectors and targets for improved cancer therapy. Curr Top Microbiol Immunol 344:173-92
McNab, Finlay W; Berry, Matthew P R; Graham, Christine M et al. (2011) Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol 41:1941-7

Showing the most recent 10 out of 97 publications